Joshua Kantrowitz
Psychiatry · Orangeburg, NYNPI 1508059304
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Merck at 54.5% of the total. Reporting peaked in 2022 at $7,082 and has fallen 86.9% since, to $925 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $309.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Neurocrine Biosciences, Inc.$2K
- Boehringer Ingelheim$870
- Voxneuro USA Inc.$500
- Immedica Pharma US, Inc.$500
- AbbVie$500
- plus $507 from 3 others
Across 124 payments — averaging $11,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$912K
- Teva Pharmaceuticals USA, Inc.$152K
- Alkermes, Inc.$136K
- Corcept Therapeutics$75K
- Boehringer Ingelheim International GmbH$57K
- H. Lundbeck A S$36K
- plus $82K from 6 others
What the payments were for
- Consulting fees$6,11555%
- Speaking & faculty fees$5004%
- Travel & lodging$3,29930%
- Food & beverage$1,24511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $6,082 |
| Neurocrine Biosciences, Inc. | 15 | $2,201 |
| Boehringer Ingelheim | 7 | $870 |
| Voxneuro USA Inc. | 1 | $500 |
| Immedica Pharma US, Inc. | 1 | $500 |
| AbbVie | 1 | $500 |
| Alkermes, Inc. | 2 | $413 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,392
- ARISTADA INITIO$348
How this compares
$11,160 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 30 | $3,393 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $761 |
| Benztropine Mesylate | 12 | $93 |
| Clonazepam | 11 | $35 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Orangeburg
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.